KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Accumulated Expenses: 2018-2025

Historic Accumulated Expenses for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $18.6 million.

  • Esperion Therapeutics' Accumulated Expenses fell 3.15% to $18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year decrease of 3.15%. This contributed to the annual value of $19.6 million for FY2024, which is 21.62% down from last year.
  • Latest data reveals that Esperion Therapeutics reported Accumulated Expenses of $18.6 million as of Q3 2025, which was up 20.61% from $15.5 million recorded in Q2 2025.
  • Esperion Therapeutics' Accumulated Expenses' 5-year high stood at $48.8 million during Q1 2021, with a 5-year trough of $5.4 million in Q4 2022.
  • For the 3-year period, Esperion Therapeutics' Accumulated Expenses averaged around $20.7 million, with its median value being $19.3 million (2023).
  • Over the last 5 years, Esperion Therapeutics' Accumulated Expenses had its largest YoY gain of 360.71% in 2023, and its largest YoY loss of 57.26% in 2023.
  • Quarterly analysis of 5 years shows Esperion Therapeutics' Accumulated Expenses stood at $7.0 million in 2021, then dropped by 22.63% to $5.4 million in 2022, then skyrocketed by 360.71% to $25.0 million in 2023, then decreased by 21.62% to $19.6 million in 2024, then declined by 3.15% to $18.6 million in 2025.
  • Its last three reported values are $18.6 million in Q3 2025, $15.5 million for Q2 2025, and $16.6 million during Q1 2025.